Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICONIC: Vopratelimab alone and in combination in advanced solid tumors
NCT02904226Phase 2Completed
- Sponsor
- Jounce Therapeutics
- Start
- Aug 2016
- Primary completion
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of vopratelimab in solid tumor (advanced stage) (8 arms), sponsored by Jounce Therapeutics. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events at 46.3 months, Number of Participants With Dose Limiting Toxicities at 33 months and 6 more. Started Aug 2016; status: completed.
02
Drugs
vopratelimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02904226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02904226.